Summary.-Five lines of human breast-carcinoma xenografts have been tested for sensitivity to cyclophosphamide, methotrexate, 5-fluorouracil, adriamycin, vincristine and melphalan, alone and in combination, using tumour growth delay as an endpoint. The xenograft lines were established and passaged in mice immune-suppressed by thymectomy and whole-body irradiation. There was a considerable range of sensitivity of the different lines to the agents studied, and within this variation there was evidence that the most effective single agent or combination differed for each tumour. Combination chemotherapy was more effective than single agents in 3 of the lines, but melphalan was more effective than either combination in the other 2. It is suggested that a panel of human breast tumours grown in immune-suppressed mice may prove useful in testing new cytotoxic agents for activity against breast cancer before their use in clinical trials, and that more effective combinations of existing drugs might be designed with the aid of this system.
ALTHOUGH COMBINATION CHEMOTHER-APY can achieve tumour regression in most patients with advanced breast cancer, responses are usually of short duration, and such treatment is rarely curative (Carter, 1976) . Even the use of adjuvant chemotherapy early in the clinical course of the disease in poor-risk patients seems likely to improve survival in only a small percentage of patients (Bonnadonna, 1980) . There is an obvious need therefore to find better drugs or better combinations of existing drugs in the treatment of this disease, and an important question is how such agents should be identified.
In this paper, we describe the response to single agents and cytotoxic drug combinations of 5 human breast-carcinoma xenografts grown and passaged in immunesuppressed mice, and we suggest that this system may be a useful model for predicting clinical chemotherapy response.
MATERIALS AND METHODS
Mice.-Female CBA/lac mice bred at the Institute of Cancer Research breeding station were used. They were thymectomized at 4 weeks of age, and 2-4 weeks later were exposed to 9 Gy whole-body irradiation, preceded 48 h earlier by 200 mg/kg cytosine arabinoside (AraC) i.p. Tumour implantation was performed on the day after irradiation. Tumours.-The 5 xenograft lines used were established and maintained in immunesuppressed mice. The technique of immune suppression of the mice and details of the initiation of the xenograft lines are fully described elsewhere (Steel et al., 1978; Bailey et al., 1980 Table I . One or other of the 2 combinations, CMF or AV, was the most effective therapy in 3 of the lines, and second most effective in 4. The mean SGD achieved for all the tumour lines by these 2 combinations was almost identical (CMF= 2-8, AV= 2.7). Of the single agents, melphalan (Me) proved the most effective overall, and in two lines (HX104 and 106) produced a greater SGD than either of the combinations. The mean growth delay seen with melphalan was 2-2, slightly longer than that attained by adriamycin (1.9) or cyclophosphamide and 5-fluorouracil, both with a mean SGD of 1-7. The performance of vincristine and methotrexate was poor in comparison with the other agents. As MTX is a cell-cycle-specific agent, it is likely that a single dose was not the most effective schedule, but an experiment in which 3 divided doses of MTX were given ,control general pattern of tumour response was initial regression, followed by a phase of slow growth, and ultimately regrowth at a rate equal to that of the control tumours. The dose-response curves for all the agents studied were linear, within the limits of experimental error, there being no evidence for either a shoulder or a plateau effect with any drug (Figs. 2-6 ). When the contribution of single agents to the combinations is studied, it can be seen that although the SGD of the combination at LD10 is greater than that of any of the single agents, the result is not greater than additive. For example, in HX105 (Fig. 5) the contribution of the single agents is shown in Table II 
DISCUSSION
Human breast tumour xenografts have been described previously in nude mice (Shimosato, 1976; Giovanella, 1976) , but the xenografts used in this study are the first reported human breast-cancer xenografts to be established and maintained in immune-suppressed animals (Bailey et al., 1980a) . The immune-suppressed mouse is about one-fifth the cost of a nude mouse, an important point when considering experimental chemotherapy studies in which several hundred mice may be needed. It is also less vulnerable to the various infections that have affected some nude mouse colonies. This study has shown that it is now possible to obtain reproducible chemosensitivity data for human breast-tumour xenografts using the technique of tumour growth delay, and has allowed us to make several important observations. First, for all 5 xenografts, combination chemotherapy was more effective than each of the single agents in the combination given alone at equitoxic dose. This does not indicate a synergistic or superadditive effect, because the data show that the growth delay achieved by each agent at the dose used in the combination summates to the growth delay of the combination itself, within the limit of experimental error. The greater cytotoxicity effect of the combination has been achieved because the toxicity to normal tissues of each agent was less than additive.
For example, the LD10 dose of CMF contains 80% of the LD1o dose of C, 90%o of F and 10%/ of M. This experimental observation reflects and reinforces a clinical principal already well established in combination chemotherapy for breast carcinoma (Carter, 1976) .
Second, there was considerable variation between the innate chemosensitivities of the tumours. For example, xenograft HX99 was more than 6 times as sensitive to the AV combination as xenograft HX104, and more than 3 times as sensitive to the combination CMF, as measured by number of volume doublings saved. This has also been shown for other human tumour xenografts, including melanoma (Selby et al., 1980) and small-cell lung carcinoma (Shorthouse et al., 1980) . Likewise, this experimental finding reflects clinical experience in breast-cancer chemotherapy, in which a small percentage of patients achieve a complete response, a larger percentage a partial response, and 30-40%o no response (Carter, 1976) . What is of great interest in this study was the further finding that the most effective drug combination or single drug varied for each tumour. In two xenografts, AV was the most effective combination, in one xenograft CMF was the most effective, and in two xenografts the single agent melphalan was more effective than either of the combinations. This variation between tumours is in contrast to a similar study recently carried out for human small-cell lung-carcinoma xenografts (Shorthouse et al., 1980 contradiction appears: melphalan was the most active single agent in all but one xenograft, and indeed was more effective than non-melphalan-containing combinations in two. In contrast clinical experience suggests that this drug is no more effective than other single agents, and is significantly less effective than combination chemotherapy (Carter, 1976) . It is possible that pharmacological differences between murine and human handling of melphalan may explain this contrast and it is equally possible that the xenografts studied are atypical in their chemosensitivity. Both of these possibilities represent valid theoretical objections to the clinical application of xenograft data. On the other hand, it may be that the melphalan data have clinical relevance, which merits further clinical examination of this drug: in most studies melphalan has been used in low doses over several days in the treatment of breast cancer, whereas the linear dose response demonstrated here suggests that intermittent high-dose therapy with this agent may be more effective and worthy of clinical trial.
It is important to note the limitations of this system to applied clinical research. First, pharmacological and pharmacokinetic differences may exist between mouse and man for at least some of the drugs used, and studies are required to investigate this further. Second, the timing of drug schedules used in the clinic is difficult to mimic in the mouse. Third, the take rate for breast-tumour xenografts is at present low (Bailey et al., 1980) and the tumours grown may be atypical in their chemosensitivity. Finally, it appears most unlikely that this system can be used to determine the most effective chemotherapy for individual patients, because of the low take rate, cost and length of time required to establish each xenograft.
On the other hand, clinical trials are time-consuming and difficult to control, and we are encouraged at the correlation already found between these experimental studies and clinical experience in treating breast carcinoma. We feel that the human breast-cancer xenograft system may well represent a valid and useful model for planning new approaches to clinical chemotherapy. Two areas in particular may prove of value. First, the system allows the contribution of each single agent to a drug combination to be evaluated. On this basis it may prove possible to design new and more effective combinations of existing drugs more quickly and more efficiently than can be currently achieved by clinical trials. Second, new drugs with potential activity can be readily tested in this series of xenografts before clinical studies. The chemosensitivity of such agents can be compared to the data already obtained for conventional agents, and it may well prove possible with this system to decide with some confidence which new agents should have the highest priority for immediate clinical studies.
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